Core Viewpoint - Sino Medical (688108) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong performance in its core business segments [1] Financial Performance - The company achieved an operating revenue of 240 million yuan, representing a year-on-year growth of 12.53% [1] - The net profit attributable to shareholders reached 13.84 million yuan, showing a remarkable year-on-year increase of 296.54% [1] - Basic earnings per share were reported at 0.03 yuan [1] Business Segment Performance - The coronary intervention business saw a revenue increase of 17.40%, primarily driven by the significant sales growth of two coronary stent products and balloon products that entered the centralized procurement scope during the reporting period [1] - The neuro-intervention business experienced a revenue growth of 6.25%, mainly due to the sales growth of newly launched products from the previous year [1]
赛诺医疗:上半年净利润1384.16万元,同比增长296.54%